Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SNY 
Sanofi ADR (SNY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: SNY (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $60.63
1 Year Target Price $60.63
| 5 | Strong Buy |
| 3 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.85% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 122.06B USD | Price to earnings Ratio 16.39 | 1Y Target Price 60.63 |
Price to earnings Ratio 16.39 | 1Y Target Price 60.63 | ||
Volume (30-day avg) 11 | Beta 0.37 | 52 Weeks Range 43.86 - 57.57 | Updated Date 11/7/2025 |
52 Weeks Range 43.86 - 57.57 | Updated Date 11/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.02 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-24 | When Before Market | Estimate 1.62 | Actual 1.6889 |
Profitability
Profit Margin 19.84% | Operating Margin (TTM) 28.73% |
Management Effectiveness
Return on Assets (TTM) 4.61% | Return on Equity (TTM) 8.84% |
Valuation
Trailing PE 16.39 | Forward PE 9.97 | Enterprise Value 129707941288 | Price to Sales(TTM) 2.62 |
Enterprise Value 129707941288 | Price to Sales(TTM) 2.62 | ||
Enterprise Value to Revenue 2.42 | Enterprise Value to EBITDA 8.77 | Shares Outstanding 2435976446 | Shares Floating 1096935593 |
Shares Outstanding 2435976446 | Shares Floating 1096935593 | ||
Percent Insiders - | Percent Institutions 10.22 |
Upturn AI SWOT
Sanofi ADR
Company Overview
History and Background
Sanofi ADR was formed in 2004 through the merger of Sanofi-Synthu00e9labo and Aventis. It traces its roots to earlier pharmaceutical companies dating back to the early 20th century. Key milestones include significant acquisitions and the development of blockbuster drugs.
Core Business Areas
- Specialty Care (Sanofi Genzyme): Focuses on rare diseases, multiple sclerosis, immunology, and oncology. Products include therapies for Pompe disease, Gaucher disease, and multiple sclerosis.
- General Medicines: Includes established products in diabetes, cardiovascular, and other therapeutic areas. Offers both prescription and over-the-counter medications.
- Vaccines (Sanofi Pasteur): One of the largest vaccine manufacturers globally, offering a range of vaccines for influenza, polio, pertussis, and other infectious diseases.
- Consumer Healthcare: Develops and markets consumer health products, including allergy medications, pain relievers, and digestive health remedies.
Leadership and Structure
The company is led by a Chief Executive Officer and has a structured management team overseeing various business units. A board of directors provides strategic oversight.
Top Products and Market Share
Key Offerings
- Dupixent: A biologic medicine used to treat atopic dermatitis, asthma, eosinophilic esophagitis, and prurigo nodularis. Generated significant revenue. Competitors: AbbVie's Rinvoq, Eli Lilly's Olumiant.
- Influenza Vaccines: A range of influenza vaccines. Competitors: GSK, CSL Seqirus.
- Plaquenil: An anti-malarial drug also used to treat lupus and rheumatoid arthritis. Competitors: Generic versions, alternatives like methotrexate.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and increasing competition from generics and biosimilars. Growing demand for innovative therapies and personalized medicine are key trends.
Positioning
Sanofi ADR is a major player in the pharmaceutical industry with a diversified portfolio of products and a strong presence in key therapeutic areas. Its competitive advantage lies in its research and development capabilities, global reach, and established brands.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated to be around $1.4 trillion and is expected to grow in the coming years. Sanofi ADR is positioned to capture a significant share of this market through its diverse product portfolio and strong market presence.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Strong R&D capabilities
- Global presence and distribution network
- Established brands and reputation
- Leading vaccine manufacturer
Weaknesses
- Exposure to patent expirations
- Dependence on key products
- Competition from generics and biosimilars
- High R&D costs
- Regulatory hurdles
Opportunities
- Expansion into emerging markets
- Development of innovative therapies
- Strategic acquisitions and partnerships
- Growth in biologics and specialty care
- Increasing demand for vaccines
Threats
- Pricing pressures and reimbursement challenges
- Generic and biosimilar competition
- Regulatory changes
- Product liability lawsuits
- Economic downturns
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- PFE
- NVS
- LLY
Competitive Landscape
Sanofi ADR faces intense competition from other major pharmaceutical companies. Its success depends on its ability to innovate, develop and market new products, and maintain its market share in key therapeutic areas.
Major Acquisitions
Translate Bio
- Year: 2021
- Acquisition Price (USD millions): 3200
- Strategic Rationale: To strengthen Sanofi's mRNA technology capabilities and accelerate the development of mRNA vaccines and therapies.
Growth Trajectory and Initiatives
Historical Growth: Historically, Sanofi ADR's growth has been driven by new product launches, acquisitions, and expansion into emerging markets.
Future Projections: Future growth is expected to be driven by innovative therapies, particularly in specialty care and vaccines. Analyst estimates vary.
Recent Initiatives: Recent strategic initiatives include focusing on key therapeutic areas, investing in R&D, and pursuing strategic acquisitions and partnerships.
Summary
Sanofi ADR is a major pharmaceutical company with strengths in vaccines, specialty care, and general medicines. While facing competition and patent expirations, it has opportunities for growth through innovation and strategic acquisitions. Sanofi needs to focus on efficient R&D and navigating regulatory landscapes. Success hinges on delivering novel therapies and maintaining market share.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company reports, investor presentations, financial news sources, market research reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sanofi ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2002-07-01 | CEO & Director Mr. Paul Hudson | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 82878 | Website https://www.sanofi.com |
Full time employees 82878 | Website https://www.sanofi.com | ||
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as a strategic alliance with the Department of Health " Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.